FDA adverse events medwatch program

被引：0
|
作者：
D. John Doyle
机构：
来源：
Canadian Journal of Anaesthesia | 2000年 / 47卷 / 11期
关键词：
D O I：
10.1007/BF03027972
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1148 / 1149
页数：1
相关论文
共 50 条
  • [41] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] SERIOUS ADVERSE EVENTS IN NORPLANT USERS REPORTED TO THE FOOD-AND-DRUG-ADMINISTRATION MEDWATCH SPONTANEOUS REPORTING SYSTEM
    SIVIN, I
    [J]. OBSTETRICS AND GYNECOLOGY, 1995, 86 (02): : 318 - 319
  • [43] MEDWATCH - THE NEW MEDICAL PRODUCTS REPORTING PROGRAM
    COUIG, MP
    MERKATZ, RB
    [J]. AMERICAN JOURNAL OF NURSING, 1993, 93 (08) : 65 - 68
  • [44] CHANGING THE CULTURE OF MEDICINE - THE FDAS MEDWATCH PROGRAM
    KESSLER, DA
    [J]. ACADEMIC MEDICINE, 1993, 68 (10) : 776 - 777
  • [45] Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
    Sonawane, Kalyani B.
    Cheng, Ning
    Hansen, Richard A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 682 - 690
  • [46] RHEUMATOLOGICAL IMMUNE-MEDIATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS BASED ON THE FDA ADVERSE EVENTS REPORTING SYSTEM
    Rodriguez-Pla, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1824 - 1825
  • [47] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [48] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [49] Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system
    Cao, Bing
    Gu, Shanshan
    Shen, Zhisen
    Zhang, Yuna
    Shen, Yiming
    Chen, Hang
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, : 297 - 303
  • [50] Novel adverse events of blonanserin: a disproportionality analysis in the FDA Adverse Event Reporting System database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Thomas
    [J]. MINERVA PSICHIATRICA, 2018, 59 (02): : 105 - 110
12345